Human epidermal growth factor receptor 2 (HER2) overexpression or amplification has long defined a high-risk molecular subtype of breast cancer, characterized by aggressive tumor progression and poor patient prognosis (8). This evidence concerns the gene ERBB2 and neoplasm.